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BACKGROUND AND OBJECTIVES   
Fibroblast growth factor (FGF) signaling is cardioprotective in various 
models of myocardial infarction.  FGF receptors (FGFRs) are expressed in 
multiple cell types in the adult heart, but the cell type-specific FGFR 
signaling which mediates different cardioprotective endpoints is currently 
unknown. 
METHODS                                                   
Mice:  To create a conditional ablation of FGFR1 and FGFR2 in endothelial cells, mice transgenic for 
Cre recombinse driven by the Tie2Cre promoter (Tie2Cre) were crossed with mice with both Fgfr1 and 
Fgfr2  genes flanked by loxP sites  (Fgfr1f/f, Fgfr2f/f).  This resulted in endothelial-specific ablation of 
FGFR1 and FGFR2 (Tie2Cre FGFR1/2 DCKO).  Wildtype controls for these experiments are double flox 
–flox or Tie2Cre controls with wildtype FGFRs. 
Mouse Model of Closed-chest Cardiac Ischemia-Reperfusion Injury:  The mouse model of closed-
chest cardiac ischemia-reperfusion injury was performed in the Mouse Cardiovascular Phenotyping Core 
at Washington University in St. Louis School of Medicine.  Mice were anesthetized with 
ketamine/xylazine (100mg/kg and 10 mg/kg, i.p.), prepped and ventilated through a tracheostomy. Mice 
were then subjected to a left mini-thoracotomy and the pericardium was dissected. An 8-0 polypropolene 
suture was passed under the proximal LAD artery, and the two ends of the  suture were threaded 
through a 0.5mm piece of PE-10 tubing forming a loose snare around the LAD (Figure 4B). The suture 
was then exteriorized through each side of the chest wall and the chest wall was closed (Figure 4B). The 
mouse was removed from the respirator and allowed to recover for seven days.  After this recovery time, 
mice were re-anesthetized but not ventilated, and only the skin above the chest wall was reopened.  
Mice were taped to an EKG board to observe ST segment changes during ischemia and reperfusion.  
The suture ends were pulled apart gently until ST segment elevation appeared on the EKG showing LAD 
occlusion and was continued for 90 minutes of ischemia time (Figure 4A).  To induce reperfusion, the 
sutures were cut close to the chest wall releasing the tension, and reperfusion was confirmed with 
resolution of ST segment elevation.  The surgeon was blinded to mouse genotype for all interventions. 
Echocardiography:  Mouse echocardiography was performed using a Visual Sonics Vevo2100 High-
Resolution In vivo Imaging System. To obtain images, mice were anesthetized with Avertin (2,2,2-
tribromoethanol, 250mg/kg, i.p.) which was chosen due to its lack of cardiovascular effects.  Ejection 
fraction was calculated by measuring the end systolic and diastolic dimensions from long-axis images 
using the following formula: 100 * ((LV end diastolic volume – LV end systolic volume / LV end diastolic 
volume). Hypokinetic area was calculated by examining serial short-axis images (1 mm apart) spanning 
from the base of the left ventricle (level of aortic valve) to the apex. The percent area of the ventricle that 
was hypokinetic was calculated by determining the percent of the ventricle with wall motion 
abnormalities. 
Histology:  Hearts were halted in diastole in potassium chloride saturated phosphate buffered saline, 
fixed in 10% formalin, and transferred to 70% ethanol the next day.  Hearts were paraffin-embedded and 
then sectioned transversely (5–10 μm).  To visualize cardiomyocyte size, heart setctions were stained 
with wheat germ agglutinin (1:4 dilution, Sigma).  To evaluate arteriole and venule remodeling, sections 
were labeled with Cy3-conjugated anti-smooth muscle acting antibody (1:500 dilution, Sigma) and 
counterstained with DAPI (Vector Laboratories).  To visualize capillary remodeling, sections were labeled 
with anti-CD31 antibody (1:20 dilution, Dianova) and Cy3 anti-rat IgG (1:5000 dilution, Sigma) and 
counterstained with DAPI.   Fluorescence was visualized using a Zeiss ApoTome microscope, and digital 
images were captured and processed with AxioVision Release 4.8 software. Images were analyzed with 
NIH Image J software.  
Statistical Analysis:  All values are expressed as mean + standard error of the mean.  
Echocardiography data for LV wall motion abnormalities and ejection fraction were compared using 
analysis of variance with a post-hoc Student’s t-test.  The remaining data were compared using a 



















Figure 1:  MTMG reporter gene expression showing induction of GFP 
expression in endothelium in Tie2Cre FGFR1/2 DCKO hearts but not 
wildtype control hearts.  
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Figure 2:  Echocardiographic determination of baseline functional 
characteristics of Tie2Cre FGFR1/2 DCKO mice.  There are no alterations 
in ejection fraction (A), fractional shortening (B), or stroke volume (C) in 








Figure 3:  Baseline quantitation of SMA positive vessel density (A) and 
capillary density (B) in non-ischemic hearts shows no difference between 









Figure 4:  Schematic (A) and  images (B) of in vivo, closed-chest, regional 









Figure 5:  Echocardiographic determination of cardiac function at 1 day 
and 7 days after in vivo IR injury.  Tie2Cre FGFR1/2 DCKO hearts show 
reduced cardiac function including ejection fraction (A), fractional 
shortening (B) and stroke volume (C) compared to wildtype control hearts 
at 7 days but not 1 day after IR injury.   n=5-6, *p<0.05 vs. wildtype. 
 
 








Figure 6:  (A) Echocardiographic determination of wall motion 
abnormalities at 1 day and 7 days after in vivo IR injury.  (B) Tie2Cre 
FGFR1/2 DCKO hearts show increased hypokinetic area compared to 
wildtype control hearts at 7 days but not 1 day after IR injury.   n=5-6, 

















Figure 7: A) Representative images of wheat germ agglutinin staining of 
the peri-infarct and remote myocardium of wildtype and Tie2Cre FGFR1/2 
DCKO hearts after 7 days of reperfusion. There is no significant difference 
in the cardiac hypertrophic response after IR injury in the remote (B) or 














Figure 8:  A) Representative images of smooth muscle actin (SMA) 
staining of the peri-infarct area of wildtype and Tie2Cre FGFR1/2 DCKO 
hearts after 7 days of reperfusion. B) Ablation of FGFR1 and FGFR2 in 
endothelium results in decreased vessel density but no change in vessel 
size after IR injury.  n=5-6. *p<0.05 vs. wildtype.   
 













Figure 9: A) Representative images of CD31 staining capillaries in the peri-
infarct area of wildtype and Tie2Cre FGFR1/2 DCKO hearts after 7 days of 
reperfusion. B) Ablation of FGFR1 and FGFR2 in endothelium results in 
decreased capillary density but no change in capillary size after IR injury.  
n=5-6. *p<0.05 vs. wildtype.  
 
 
SUMMARY       
 Ablation of FGFR1 and FGFR2 in endothelial cells has no baseline effect 
on cardiac function or vessel density (both arteriole and capillary). 
 
 After in vivo, closed-chest cardiac IR injury, FGFR1 and FGFR2 ablation 
in endothelial cells resulted in reduced cardiac function and increased wall 
motion abnormalities at 7 days but not 1 day of reperfusion.   
 
 Ablation of FGFR1 and FGFR2 in endothelial cells does not effect the 
cardiac hypertrophic response to IR injury. 
 
 Vascular remodeling after IR injury is impaired in mice with endothelial-




CONCLUSION      
Ablation of FGFR1 and FGFR2 in endothelial cells results in impaired 
vascular remodeling, worsened cardiac functional recovery, and increased 
infarct size without affecting the cardiac hypertrophic response in an in vivo, 
closed-chest model of cardiac ischemia-reperfusion injury. 
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